The Bio/Pharmaceutical Outsourcing Report is a monthly analysis of news and trends affecting pharmaceutical Contract Manufacturing Organizations (CMOs). It includes in-depth analyses of the latest business conditions, lists new outsourcing contracts, assesses the latest opportunities and threats for manufacturers, and identifies recent mergers, acquisitions, and financing among CMOs. It also updates readers on facility-level news, such as planned site openings and closures, Good Manufacturing Practice (GMP) inspections, and investments in technology and equipment.
Scope
This report gives an important monthly update on the pharmaceutical outsourcing industry, based on analysis from the analyst's experts and our databases covering deals, companies, drugs, financials, news, clinical trials, and more. This report is required reading for:- CMO executives and strategic decision-makers: to improve understanding of the CMO industry and provide a critical input for strategic planning efforts.
- Sourcing and procurement executives in bio/pharmaceutical companies: to improve understanding of crucial components of the supply base that will provide insights for supplier selection and management.
- Investors, advisors, and consultants: they can gain a deeper understanding of the CMO market and important insights for identifying potential investment targets.
Reasons to Buy
- Understand current trends and equip yourself with forward-thinking strategies to navigate challenges and capitalise on emerging trends driving the pharmaceutical manufacturing industry. Use our radar to identify developments and innovations with high impact.
- Discover the latest opportunities and threats in the contract manufacturing industry, based on clinical trials and regulatory decisions.
- Learn about the past quarter’s M&A and financing deals in the manufacturing space.
- Identify the latest contract service agreements.
- Develop your competitor or market intelligence by reading about inspection outcomes and facility investments.
- Stay ahead of disruption with updates on supply chain obstacles and new regulations.
Table of Contents
1 Industry Trends
List of Tables
List of Figures
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Novo Nordisk
- Novartis
- AstraZeneca
- Eli Lilly
- Roche
- Johnson & Johnson
- Genentech
- Vaxart
- AGC Biologics Inc
- Andelyn Biosciences Inc
- Anemocyte Srl
- Catalent France Limoges SAS
- Cell and Gene Therapy Catapult
- Cellipont Bioservices
- FUJIFILM Diosynth Biotechnologies USA Inc
- GeneFab LLC
- Genezen Laboratories Inc
- Lotte Biologics Co Ltd
- PolyPeptide Group AG
- ProBioGen AG
- Samsung Biologics Co Ltd
- Vetter Pharma-Fertigung GmbH & Co KG
- Viralgen Vector Core SL
- AbbVie Inc
- Biogen Inc
- Boehringer Ingelheim Pharma GmbH & Co KG
- Catalent Inc
- Delpharm SAS
- Divi's Laboratories Ltd
- Esteve Quimica SA
- Excella GmbH & Co KG
- Fareva SA
- Gland Pharma Ltd
- Hetero Drugs Ltd
- Janssen-Cilag International NV
- Lonza Group Ltd
- MilliporeSigma
- Novartis AG
- Organon & Co
- PCI Pharma Services
- Piramal Pharma Solutions Inc
- Samsung Biologics Co Ltd
- WuXi Biologics Co Ltd
- Thermo Fisher Scientific Inc
- Gilead Sciences Inc
- Recipharm AB
- Matica Biotechnology Inc
- Minaris Advanced Therapies LLC
- SK Pharmteco Inc
- Empower Pharmacy
- Nubratori Inc
- Wesley Pharmaceuticals LLC
- Argent BioPharma Ltd
- Fermion Oy
- Bionova Scientific Inc
- BioWell
- Xellia Pharmaceuticals ApS
- CCRM Nordic AB
- NecstGen BV
- Northway Biotech UAB
- Amneal Pharmaceuticals Inc
- BDR Pharmaceuticals Internationals Pvt Ltd
- Galena Pharma Oy
- Meribel Pharma Solutions
- Symbiosis Pharmaceutical Services Ltd
- The Ritedose Corp
- Eubioco SA
- Intertek Group Plc
- Spera Pharma Inc
- Rigaku Holdings Corp
